Home » CELLEGY TO STOP HIV TRANSMISSION STUDY IN GHANA
CELLEGY TO STOP HIV TRANSMISSION STUDY IN GHANA
Cellegy Pharmaceuticals Inc. (CLGY.O: Quote, Profile, Research) on Tuesday said it will stop a late-stage study of its vaginal gel on preventing HIV infection in Ghana because of a lower-than-expected rate of transmission of the virus. Cellegy said the lower rate was possibly due in part to counseling on HIV prevention and the distribution of condoms.
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May